The 8-day notice: how a compounding wind-down works in Spain
The document is four pages. Three of them are about dates.
Shortage listings
Page 5 of 13 of this archive, newest first.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The 16-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
The 8-day notice: how a compounding wind-down works in Singapore
The document is four pages. Three of them are about dates.
What happens when the drug is taken away: three randomised answers
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
What the placebo arms of the withdrawal trials actually tell us
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The 22-day notice: how a compounding wind-down works in the Netherlands
The document is four pages. Three of them are about dates.
A shortage listing ends. 15 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 11-day notice: how a compounding wind-down works in Mexico
The document is four pages. Three of them are about dates.
The 29-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
Coming off: what the pharmacology permits
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
There is no discontinuation syndrome, and that changes the argument
The best argument for tapering is behavioural rather than pharmacological, and it deserves to be made on its own terms.
The 21-day notice: how a compounding wind-down works in the United Arab Emirates
The document is four pages. Three of them are about dates.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 30-day notice: how a compounding wind-down works in Switzerland
The document is four pages. Three of them are about dates.